
NewLimit Raises $435M Series C for Human Longevity Trials
NewLimit, a South San Francisco startup, raised $435 million in Series C funding, bringing its total funding to about $682 million and valuing the company at $3.1 billion. This funding suggests NewLimit may soon begin human trials for its epigenetic-reprogramming therapies, which aim to restore youthful cell function. The company plans to use the money for its first human liver trial, which might start next year if manufacturing and hiring go as planned. Investors appear interested even though the science is still emerging, and success in early trials could help similar approaches. It is not yet certain if this will lead to the first approved epigenetic reprogramming drug in humans.













